{"id":"recombinant-human-insulin-patch-zjsrm2021","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions (or patch site reactions)"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL1201540","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a recombinant human insulin formulation administered through a transdermal patch system, allowing insulin to be absorbed through the skin rather than via injection. Insulin binds to insulin receptors on target cells, promoting glucose uptake and utilization while suppressing hepatic glucose production, thereby normalizing blood glucose in diabetic patients.","oneSentence":"Recombinant human insulin delivered via transdermal patch replaces deficient endogenous insulin to regulate blood glucose levels.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:36:57.963Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05089942","phase":"PHASE4","title":"Efficacy and Safety of Recombinant Human Insulin Patch ZJSRM2021","status":"UNKNOWN","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2021-12","conditions":"type1diabetes, Type2 Diabetes","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Recombinant Human Insulin Patch ZJSRM2021","genericName":"Recombinant Human Insulin Patch ZJSRM2021","companyName":"Zhejiang Provincial People's Hospital","companyId":"zhejiang-provincial-people-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Recombinant human insulin delivered via transdermal patch replaces deficient endogenous insulin to regulate blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}